Risperidone release from Solid Lipid Nanoparticles (SLN): Validated HPLC method and modelling kinetic profile

Current Pharmaceutical Analysis

Volumn 8, Issue 4, 2012, Pages 307-316

  Silva, A C ^a,b   Lopes, C M ^b,c   Fonsecaa, J ^a   Soares, M E ^a   Santos, D ^a   Souto, E B ^b,c   Ferreira, D ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Controlled drug release; Encapsulation efficiency; Encapsulation parameters; High performance liquid chromatography; Kinetic model; Loading capacity; Oral drug delivery; Release profile; Risperidone; Solid lipid nanoparticles

Indexed keywords

DEOXYCHOLATE SODIUM; GLYCEROL STEARATE; IMWITOR; MACROGOL DERIVATIVE; RISPERIDONE; SOLID LIPID NANOPARTICLE; TAGAT S; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DIFFUSION; DRUG DETERMINATION; ENCAPSULATION; KINETICS; MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 84857786253     PISSN: 15734129     EISSN: 1875676X     Source Type: Journal    
DOI: 10.2174/157341212803341663     Document Type: Article

References (40)

1. The United States Pharmacopeia, United States Pharmacopeia/The National Formulary United States Pharmacopeial Convention: Rockville, MD, 2008.
2. Bhanji, N.H.; Chouinard, G.; Margolese, H.C. A review of compliance, depot intramuscular antipsychotics and the new longacting injectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol 2004, 14 87-92.
3. Chue, P.; Welch, R.; Binder, C. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can. J. Psychiatry 2004, 49 701-703.
4. Chue, P.; Prinzo, R.S.; Binder, C.E. Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets. Hum. Psychopharmacol 2007, 22 307-314.
5. Kumar, M.; Misra, A.; Babbar, A.K.; Mishra, A.K.; Mishra, P.; Pathak, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008, 358(1-2), 285-291.
6. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability. Pharm. Res 1995, 12 413-420.
7. Costa, P.; Sousa Lobo, J.M. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13 123-133.
8. Muller, R.H.; Keck, C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004, 113 151-170.
9. Pouton, C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 2006, 29 278-287.
10. Hauss, D.J. Oral lipid-based formulations. Adv. Drug Deliv. Rev 2007, 59 667-676.
11. Muller, R.H.; Shegokar, R.; Keck, C.M. 20 Years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol 2011, 8(3), 207-27.
12. Souto, E.B.; Muller, R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol 2011, 197 115-141.
13. Das, S.; Chaudhury, A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2010, 12 62-76.
14. Ermer, J.; Ploss, H.J. Validation in pharmaceutical analysis. Part II: central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data. J. Pharm. Biomed. Anal 2005, 37 859-870.
15. LoBrutto, R.; Patel, T. Method Validation, In: HPLC for Pharmaceutical Scientists Kazakevich, Y.; LoBrutto, R.; Eds.; John Wiley & Sons: New York, 2007, pp. 455-502.
16. Ermer, J. Validation in pharmaceutical analysis. Part I: an integrated approach. J. Pharm. Biomed. Anal 2001, 24 755-767.
17. ICH-Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1) Current Step 4 version; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.
18. El-Sherif, Z.A.; El-Zeany, B.; El-Houssini, O.M. High p4 erformance liquid chromatographic and thin layer densitometric methods for the determination of risperidone in the presence of its degradation products in bulk powder and in tablets. J. Pharm. Biomed. Anal 2005, 36 975-981.
19. Batool, F.; Hasnat, A.; Haleem, M.A.; Haleem, D.J. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Acta Pharm. 2010, 60 129-140.
20. Zhang, G.; Terry, A.V. Jr.; Bartlett, M.G. Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2007, 856 20-28.
21. Mandrioli, R.; Mercolini, L.; Lateana, D.; Boncompagni, G.; Raggi, M.A. Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV. J. Chromatogr. B Analyt Technol. Biomed. Life Sci 2011, 879 167-173.
22. Ould-Ouali, L.; Noppe, M.; Langlois, X.; Willems, B.; Te Riele, P.; Timmerman, P.; Brewster, M.E.; Arien, A.; Preat, V. Selfassembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J. Control. Release 2005, 102 657-668.
23. Kumar, M.; Pathak, K.; Misra, A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev. Ind. Pharm 2009, 35 387-395.
24. Muthu, M.S.; Rawat, M.K.; Mishra, A.; Singh, S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine 2009, 5 323-333.
25. Muthu, M.S.; Singh, S. Poly (D, L-lactide) nanosuspensions of risperidone for parenteral delivery: formulation and in-vitro evaluation. Curr. Drug Deliv 2009, 6 62-68.
26. Woestenborghs, R.; Lorreyne, W.; Van Rompaey, F.; Heykants, J. Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J. Chromatogr 1992, 583 223-230.
27. Silva, A.C.; Gonzalez-Mira, E.; Garcia, M.L.; Egea, M.A.; Fonseca, J.; Silva, R.; Santos, D.; Souto, E.B.; Ferreira, D. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloids Surf. B Biointerfaces 2011, 86 158-165.
28. Patil, M.N.; Pandit, A.B. Cavitation-a novel technique for making stable nano-suspensions. Ultrason. Sonochem 2007, 14 519-530.
29. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50 161-177.
30. Araujo, J.; Gonzalez-Mira, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 2010, 393 167-175.
31. Gonzalez-Mira, E.; Egea, M.A.; Souto, E.B.; Calpena, A.C.; Garcia, M.L. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011, 22(4), 045101.
32. Vivek, K.; Reddy, H.; Murthy, R.S. Investigations of the effect of the lipid matrix on drug entrapment, in vivo release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007, 8(4), E83.
33. Dressman, J.B.; Amidon, G.L.; Reppas, C.; Shah, V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res 1998, 15 11-22.
34. Shabir, G.A. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J. Chromatogr. A 2003, 987 57-66.
35. Muller, R.H.; Runge, S.; Ravelli, V.; Mehnert, W.; Thunemann, A.F.; Souto, E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 2006, 317 82-89.
36. Muller, R.H.; Runge, S.A.; Ravelli, V.; Thunemann, A.F.; Mehnert, W.; Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm 2008, 68 535-544.
37. Muchow, M.; Maincent, P.; Muller, R.H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 2008, 34 1394-1405.
38. Abdelbary, G.; Fahmy, R.H. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech 2009, 10 211-219.
39. Ritger, P.L.; Peppas, N.A. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release 1987, 5 23-36.
40. Ritger, P.L.; Peppas, N.A. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 1987, 5 37-42.